GENEVA--(BUSINESS WIRE)--Endosense, a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment of the first patients in its ProForce Registry. The news marks the launch of the ProForce Registry Study, an international, single arm, multi-center, post-market trial of Endosense’s TactiCath force-sensing ablation catheter. Designed to enroll up to 2,000 patients, the ProForce Registry Study will evaluate the use and impact of contact force monitoring during catheter ablation procedures.
